Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients...
Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero,...
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical...
LEWES, Del., Dec. 11, 2024 /PRNewswire/ --The CRO Services Market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource...
PHILADELPHIA, Dec. 11, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the...
RESTON, Va., Dec. 11, 2024 /PRNewswire/ -- Leidos (NYSE: LDOS) today announced a $2.5 million donation to The Children's Inn at the...
Domi strengthens the #AiresAthletes campaign, reinforcing the importance of protection from EMF radiation to enhance recovery and overall well-being* Domi...
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage...
Halifax, Nova Scotia--(Newsfile Corp. - December 11, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces...
Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London.Toronto, Ontario--(Newsfile Corp. - December 11, 2024) -...
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for...
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the...
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is...
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug,...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will...
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 –...
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage...
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive...
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster,...